Table 3.

Summary of overlap between differentially spliced genes identified in multiple human AD splicing studies and mouse models. Number of differentially spliced genes identified in splicing analyses of human AD cohort in multiple studies. Significant overlap with differentially exon usage genes in mouse models were computed using hypergeometric test (p < 0.05). Control-AsymAD represents comparison between asymptomatic AD cases and controls. AsymAD-AD represents comparison between AD cases and asymptomatic AD cases. Control-AD represents comparison between AD cases and controls

	Differentially Spliced Genes	Overlap with 12 mo. Trem2 male mice (207 DEU)	Overlap across all mouse models (1167 DEU)
ROSMAP	67	8 (p = 2.78E-06)	12 (p = 0.004)
TMT Proteomic Study (Control-AsymAD)	155	6 (p = 0.017)	27 (p = 0.001)
TMT Proteomic Study (AsymAD-AD)	291	10 (p = 0.005)	34 (p = 0.10)
TMT Proteomic Study (Control-AD)	237	5 (p = 0.20)	26 (p = 0.18)
Emory/Kentucky	536	13 (p = 0.03)	55 (p = 0.01)